上期（总第228期）A股绿色周报显示，共有4家上市公司在近期暴露了环境风险。 每经AI快讯，"A股绿色报告"项目监控到的数据显示，恒瑞医药（600276）控股子公司福建盛迪医药有限公司福建盛迪高端原料药基地 二期建设项目环评审批获同意。该项目总投资额达2.5亿元。该审批信息于2025年12月26日被相关监管机构披露。 "A股绿色报告"项目由每日经济新闻联合环保领域知名NGO公众环境研究中心（IPE）共同推出，旨在让上市公司环境信息更加阳光透 明。本项目基于31个省（区、市）、337个地级市政府发布的权威环境监管数据，筛选监控上市公司及其旗下公司（包括分公司、参股 公司和控股公司）的环境表现，加以专业数据分析及深入解读，每日智能写作及时发布上市公司AI绿报，每周推出A股绿色周报，定期 动态更新上市公司环境风险榜。 (记者 刘志远 魏文艺) 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前核实。据此操作，风险自担。 ...

格隆汇1月12日丨赤天化(600227.SH)公布，公司财务部门初步测算，预计2025年年度归属于上市公司股 东的净利润为负值，公司2025年年度经营业绩将出现亏损。 ...

Market Overview - The A-share market indices collectively rose today, with total trading volume exceeding 3.6 trillion yuan, marking the second consecutive trading day above 3 trillion yuan, an increase of 478.7 billion yuan compared to the previous trading day, setting a new historical record for trading volume in 2024 [1] Index Performance - The Shanghai Composite Index closed at 4165.29 points, up 1.09%, with a trading volume of 1.446 trillion yuan - The Shenzhen Component Index closed at 14366.91 points, up 1.75%, with a trading volume of 2.155 trillion yuan - The ChiNext Index closed at 3388.34 points, up 1.82%, with a trading volume of 1.086 trillion yuan [1] Sector Performance - The leading sectors in terms of growth included: - Cultural Media: up 7.96%, with a trading volume of 724.48 billion yuan and a net inflow of 94.79 billion yuan - IT Services: up 7.92%, with a trading volume of 822.49 billion yuan and a net inflow of 122.25 billion yuan - Software Development: up 7.76%, with a trading volume of 640.22 billion yuan and a net inflow of 214.60 billion yuan [2] Declining Sectors - The sectors with the largest declines included: - Insurance: down 0.81%, with a trading volume of 18.93 billion yuan and a net outflow of 10.62 billion yuan - Oil and Gas Extraction and Services: down 0.34%, with a trading volume of 164.48 billion yuan and a net outflow of 8.16 billion yuan - Agricultural Chemicals: down 0.22%, with a trading volume of 182.31 billion yuan and a net outflow of 22.81 billion yuan [2]

*ST景峰再度涨停，4个交易日内录得3个涨停，累计涨幅为20.26%，累计换手率为5.71%。截至9:25， 该股今日成交量105.03万股，成交金额860.17万元，换手率0.12%。最新A股总市值达72.05亿元。 龙虎榜数据显示，该股因连续三个交易日内，收盘价涨幅偏离值累计达到12%的ST证券、*ST证券上榜 龙虎榜1次，买卖居前营业部中，机构净卖出30.82万元，营业部席位合计净买入1114.16万元。 据天眼查APP显示，湖南景峰医药股份有限公司成立于1998年12月18日，注册资本87977.4351万人民 币。（数据宝） 近日该股表现 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2026.01.09 | 3.86 | 3.60 | -749.81 | | 2026.01.08 | 5.03 | 0.55 | 1024.69 | | 2026.01.07 | 4.99 | 1.45 | 1300.97 | | 2026.01.06 | -1.30 | 2.17 | -3094.21 | | 2026.01 ...

Group 1 - Garden Biologics experienced a stock decline of 0.90% on January 9, with a trading volume of 484 million yuan [1] - The company had a net financing purchase of 22.48 million yuan on the same day, with a total financing balance of 683 million yuan, accounting for 7.62% of its market capitalization [1] - The company’s financing balance is above the 60th percentile of the past year, indicating a high level of financing activity [1] Group 2 - As of December 31, the number of shareholders for Garden Biologics decreased by 12.35% to 26,200, while the average circulating shares per person increased by 14.09% to 20,383 shares [2] - For the period from January to September 2025, the company reported a revenue of 936 million yuan, a slight decrease of 0.20% year-on-year, and a net profit of 234 million yuan, down 3.07% year-on-year [2] - The company has distributed a total of 446 million yuan in dividends since its A-share listing, with 178 million yuan distributed in the last three years [2]

Group 1 - The report highlights the launch of "ChatGPT Health" by OpenAI, which integrates health-related conversations and connects to electronic medical records, indicating a significant potential market for AI in healthcare [9][12] - The "Artificial Intelligence + Manufacturing" initiative aims to achieve reliable supply of core AI technologies and maintain a leading position in the industry by 2027, with specific targets including the application of 3-5 general large models in manufacturing and the creation of 100 high-quality industrial datasets [12][14] - The report identifies key sectors such as AI healthcare, AI pharmaceuticals, and AI biomanufacturing as focal points for development, proposing measures like building intelligent drug discovery platforms and smart supply chain management systems [16][12] Group 2 - The North Exchange's biopharmaceutical sector saw a weekly increase of 5.85%, with medical devices rising by 7.81%, indicating strong market performance [23][26] - Among the biopharmaceutical companies, 90.48% experienced stock price increases, with notable performers including BeiYikang (+45.1%) and XinGanjian (+10.46%) [33][34] - As of January 9, 2026, there are 15 companies in the biopharmaceutical sector awaiting approval on the North Exchange, with an average projected revenue of 424 million yuan for 2024 [34][38] Group 3 - The report emphasizes the importance of AI in enhancing drug development efficiency and supply chain management, aiming to reduce costs and time in pharmaceutical processes [16][12] - The global AI healthcare market is projected to reach approximately $26.65 billion in 2024, with a compound annual growth rate (CAGR) of 38.8% expected until 2033 [18][17] - The Chinese AI healthcare industry is expected to grow from 97.3 billion yuan in 2023 to 159.8 billion yuan by 2028, reflecting significant growth potential in this sector [18][19]

Core Viewpoint - The A-share annual report season is progressing, with 87 companies releasing their 2025 annual performance forecasts, leading to significant stock price movements, including a limit-up for Nanxing Co., Ltd. [1] Group 1: Company Performance Forecasts - 17 companies, including Zhongke Lanyun, Chuanhua Zhili, Kangchen Pharmaceutical, and others, are expected to see a year-on-year increase in net profit exceeding 100% [1] - Zhongke Lanyun leads with an anticipated net profit of 1.4 billion to 1.43 billion yuan, reflecting a growth of 366.51% to 376.51% compared to the previous year, primarily due to significant gains from investments [1] - Chuanhua Zhili forecasts a net profit of 540 million to 700 million yuan, representing a growth of 256.07% to 361.57%, driven by optimized marketing strategies and asset structure in its logistics business [2] - Kangchen Pharmaceutical expects a net profit of 145 million to 175 million yuan, an increase of 243% to 315%, with no impact from goodwill impairment in the current reporting period [2] Group 2: Specific Company Highlights - Nanxing Co., Ltd. projects a net profit of 90 million to 120 million yuan for 2025, recovering from a loss of 175 million yuan in the previous year, attributed to reduced goodwill impairment impact and growth in its IDC business [3]

Core Viewpoint - ST诺泰 (688076) has shown a price increase of 3.1% this week, closing at 38.87 yuan as of January 9, 2026, with a total market capitalization of 12.285 billion yuan [1] Company Announcements Summary - On December 17, 2025, ST诺泰 received an administrative penalty decision from the China Securities Regulatory Commission (CSRC) and a disciplinary decision from the Shanghai Stock Exchange [1] - Nanjing Securities, as the sponsor, conducted an on-site inspection of 诺泰生物 from January 1, 2025, to the inspection period, covering aspects such as corporate governance, information disclosure, use of raised funds, related party transactions, and external guarantees [1] - The inspection found that corporate governance and internal controls were effective, information disclosure was true and accurate, and the use of raised funds was compliant, with no violations in related party transactions, external guarantees, or significant external investments [1]

Core Viewpoint - The recent acquisition of a 9.75% stake in Daxin Pharmaceutical by Peking University Pharmaceutical is a strategic move to regain control over a previously divested asset, despite the company's ongoing financial struggles and the associated risks of the transaction [2][4][6]. Group 1: Acquisition Details - Peking University Pharmaceutical acquired the 9.75% stake in Daxin Pharmaceutical for 22 million yuan, with the transaction being completed swiftly on the same day as the auction [3][4]. - The total equity value of Daxin Pharmaceutical is approximately 233 million yuan, with a valuation increase of 28.52% [4]. - The stake was previously pledged as collateral for a debt of approximately 1.32 billion yuan owed by Southwest Synthesis to Peking University Medical Group [5]. Group 2: Financial Performance of Daxin Pharmaceutical - Daxin Pharmaceutical reported a revenue of approximately 269 million yuan in 2024, with a loss of 27.48 million yuan, and a revenue of about 212 million yuan with a net profit of 63,600 yuan in the first eight months of 2025 [6]. - The company's net assets have decreased to approximately 181 million yuan, reflecting a significant decline from 271 million yuan in 2015 [6]. Group 3: Ongoing Legal and Operational Challenges - Peking University Pharmaceutical is involved in an arbitration case with Chongqing Synthesis regarding an asset transfer agreement, which has resulted in a ruling that may lead to increased operational costs due to personnel management issues [7][8]. - The company faces a potential revenue loss of approximately 600 million yuan and a net profit decrease of about 40 million yuan due to the termination of a long-term service contract with Peking University International Hospital [9]. - In the third quarter of 2025, Peking University Pharmaceutical experienced a 47.95% year-on-year decline in revenue, amounting to approximately 274 million yuan [9].

证券日报网讯 1月9日，海南海药发布公告称，持有海南海药股份有限公司（简称"本公司"）股份68， 295，512股（占本公司总股本比例5.26%）的股东云南国际信托有限公司－聚利36号单一资金信托计划 在本公告披露之日起15个交易日后的连续90个自然日内以集中竞价交易方式减持本公司股份不超过12， 973，651股，占本公司总股本的1%。 （文章来源：证券日报） ...